Imatinib (4)

Pharmacogenomic Information

DrugTherapeutic Area*BiomarkerReferenced
Labeling Sections
ImatinibOncologyFIP1L1-PDGFRAFIP1L1-PDGFRα fusion
kinase (or CHIC2 deletion) positive
Indications and Usage
Dosage and Administration
Clinical Studies 


* Therapeutic areas do not necessarily reflect the CDER review division.
† Standard nomenclature is used for genes as per the Human Genome Organization symbol, cytogenetic abnormalities as per the International System for Human Cytogenetic Nomenclature, or other conventions.


back to Pharmacogenomic Biomarkers in Drug Labeling

Page Last Updated: 04/14/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.